These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10340106)

  • 41. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TNF-alpha inhibitors offer hope to RA patients.
    Wimett L
    Nurse Pract; 2003 Oct; 28(10):40-8. PubMed ID: 14560130
    [No Abstract]   [Full Text] [Related]  

  • 43. Guidance for practitioners on the assessment, administration and monitoring of biologic therapies for inflammatory arthritis.
    Oliver S
    Musculoskeletal Care; 2003 Sep; 1(2):135-40. PubMed ID: 20217674
    [No Abstract]   [Full Text] [Related]  

  • 44. Cytokines in rheumatoid arthritis: trials and tribulations.
    Carteron NL
    Mol Med Today; 2000 Aug; 6(8):315-23. PubMed ID: 10904249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Etanercept tolerance in a patient with previous infliximab-induced hepatitis.
    Becker H; Willeke P; Domschke W; Gaubitz M
    Clin Rheumatol; 2008 Dec; 27(12):1597-8. PubMed ID: 18795397
    [No Abstract]   [Full Text] [Related]  

  • 46. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.
    Anderson P; Louie J; Lau A; Broder M
    Curr Rheumatol Rep; 2005 Mar; 7(1):3-9. PubMed ID: 15760575
    [No Abstract]   [Full Text] [Related]  

  • 47. [Cytokines and anti-cytokine therapy in rheumatoid arthritis].
    Lorenz HM; Kalden JR
    Internist (Berl); 2001 Jan; 42(1):55-6, 59-63. PubMed ID: 11271621
    [No Abstract]   [Full Text] [Related]  

  • 48. Adalimumab-associated multiple sclerosis.
    Bensouda-Grimaldi L; Mulleman D; Valat JP; Autret-Leca E
    J Rheumatol; 2007 Jan; 34(1):239-40; discussion 240. PubMed ID: 17216704
    [No Abstract]   [Full Text] [Related]  

  • 49. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 50. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
    Jobanputra P; Barton P; Bryan S; Burls A
    Health Technol Assess; 2002; 6(21):1-110. PubMed ID: 12387732
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France.
    Fautrel B; Woronoff-Lemsi MC; Ethgen M; Fein E; Monnet P; Sibilia J; Wendling D
    Joint Bone Spine; 2005 Dec; 72(6):550-6. PubMed ID: 15996504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New drugs for the treatment of rheumatoid arthritis.
    Schuna AA; Megeff C
    Am J Health Syst Pharm; 2000 Feb; 57(3):225-34. PubMed ID: 10674776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.
    Feldman M; Taylor P; Paleolog E; Brennan FM; Maini RN
    Transplant Proc; 1998 Dec; 30(8):4126-7. PubMed ID: 9865320
    [No Abstract]   [Full Text] [Related]  

  • 54. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
    Richard-Miceli C; Dougados M
    BioDrugs; 2001; 15(4):251-9. PubMed ID: 11437690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis.
    Kubota T; Nii T; Nanki T; Kohsaka H; Harigai M; Komano Y; Sugihara T; Nonomura Y; Hirose W; Nagasaka K; Sakurai T; Miyasaka N
    Mod Rheumatol; 2007; 17(6):531-3. PubMed ID: 18084712
    [No Abstract]   [Full Text] [Related]  

  • 59. [Inhibitors of TNFalpha].
    Brousse C
    Rev Med Interne; 2003 Feb; 24(2):123-6. PubMed ID: 12650894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.
    Hochberg MC; Tracy JK; Hawkins-Holt M; Flores RH
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii13-6. PubMed ID: 14532140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.